{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T19:03:27Z","timestamp":1773947007693,"version":"3.50.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Rilpivirine has shown adequate antiviral activity, consistent pharmacokinetics and safety in adults and adolescents living with HIV-1. Pharmacokinetics, safety, and antiviral activity of rilpivirine were assessed in children, following at least 48 weeks of treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Cohort 2 of the open-label, phase 2 PAINT study (NCT00799864) included antiretroviral-na\u00efve children living with HIV-1 \u22656 to &lt;12 years old, with a viral load \u2264100,000 RNA copies\/mL. Participants received weight-based doses of rilpivirine in combination with a background regimen containing 2 nucleoside\/nucleotide reverse transcriptase inhibitors (NRTIs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of the 18 children enrolled, 17 completed the 48-week treatment period. Participants were mostly boys (61%), median (range) age of 9.0 years (6\u201311 years) and weight of 25.0\u2009kg (17\u201351\u2009kg). Most children [14\/18 (78%)] were adherent (&gt;95%) to the treatment. Pharmacokinetic exposures were similar across the recommended weight-based doses and within a range comparable to exposures seen in adult studies. At week 48, 13\/18 (72%) children achieved virologic response (HIV-1 RNA &lt;50 copies\/mL, FDA Snapshot). The mean (SE) increase from baseline to week 48 in CD4+ count was 213.4 (77.80) cells\/\u03bcL. Overall postbaseline, 2 participants experienced virologic failure, of which 1 carried treatment-emergent rilpivirine resistance-associated mutations (RAMs); 3 of 5 participants with suspected virologic failure carried rilpivirine and NRTI RAMs. No new safety signals were identified in this population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>At week 48, rilpivirine achieved adequate viral suppression in antiretroviral-na\u00efve children \u22656 to &lt;12 years of age. The pharmacokinetic, safety and virologic profile of rilpivirine in this age group was consistent with observations in adults and adolescents living with HIV-1.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004828","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T18:00:10Z","timestamp":1744999210000},"page":"657-664","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetics, Safety and Antiviral Activity of Rilpivirine in Antiretroviral-na\u00efve Children With HIV \u22656 to &lt;12 Years Old: Week 48 and Final Analysis of Cohort 2 From the Open-label, Phase 2 PAINT Study"],"prefix":"10.1097","volume":"44","author":[{"given":"Johan","family":"Lombaard","sequence":"first","affiliation":[{"name":"Josha Research, Bloemfontein, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Visal","family":"Moolasart","sequence":"additional","affiliation":[{"name":"Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Lutaakome","sequence":"additional","affiliation":[{"name":"MRC\/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodica","family":"Van Solingen-Ristea","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veerle","family":"Van Eygen","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy","family":"Van Hemelryck","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharne","family":"Foulkes","sequence":"additional","affiliation":[{"name":"Josha Research, Bloemfontein, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Natukunda","sequence":"additional","affiliation":[{"name":"Joint Clinical Research Centre, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Kurosawa","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minaka","family":"Shibuya","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Vanveggel","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Van Landuyt","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Beerse, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Ssali","sequence":"additional","affiliation":[{"name":"Joint Clinical Research Centre, Kampala, Uganda"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"R1-20250613","article-title":"Summary of the global HIV epidemic.","year":"2023"},{"key":"R2-20250613","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1186\/s12887-022-03693-5","article-title":"Survival time and predictors of death among HIV infected under five children after initiation of anti-retroviral therapy in West Amhara Referral Hospitals, Northwest Ethiopia.","volume":"22","author":"Alemu","year":"2022","journal-title":"BMC Pediatr"},{"key":"R3-20250613","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/QAD.0000000000003086","article-title":"Causes of death in HIV-infected and HIV-uninfected children aged under-five years in western Kenya.","volume":"36","author":"Onyango","year":"2022","journal-title":"AIDS"},{"key":"R4-20250613","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1473-3099(11)70141-4","article-title":"HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.","volume":"11","author":"Sigaloff","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1473-3099(02)00183-4","article-title":"Efficacy of highly active antiretroviral therapy in HIV-1 infected children.","volume":"2","author":"van Rossum","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"R6-20250613","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1097\/00002030-200409240-00007","article-title":"Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study.","volume":"18","author":"Walker","year":"2004","journal-title":"AIDS"},{"key":"R7-20250613","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(11)60208-0","article-title":"Risk of triple-class virological failure in children with HIV: a retrospective cohort study.","volume":"377","author":"Castro","year":"2011","journal-title":"Lancet"},{"key":"R8-20250613","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1086\/313849","article-title":"Factors affecting adherence to antiretroviral therapy.","volume":"30","author":"Chesney","year":"2000","journal-title":"Clin Infect Dis"},{"key":"R9-20250613","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/s10461-015-1207-7","article-title":"Adherence to antiretroviral therapy among children living with HIV in South India.","volume":"20","author":"Mehta","year":"2016","journal-title":"AIDS Behav"},{"key":"R10-20250613","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/QAD.0000000000003835","article-title":"HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: a multicentre cohort study.","volume":"38","author":"Devendra","year":"2024","journal-title":"AIDS"},{"key":"R11-20250613","doi-asserted-by":"crossref","first-page":"e33737","DOI":"10.1097\/MD.0000000000033737","article-title":"Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: children at high risk of virological failure due to the lowly transition in pediatrics.","volume":"102","author":"Fokam","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"R12-20250613","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/INF.0000000000002577","article-title":"Outcomes of integrase inhibitor-based antiretroviral therapy in a clinical cohort of treatment-experienced children, adolescents and young adults with HIV infection.","volume":"39","author":"Levy","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"R13-20250613","article-title":"Highlights of prescribing information.","year":"2024"},{"key":"R14-20250613","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/QAI.0b013e31824d006e","article-title":"Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.","volume":"60","author":"Cohen","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R15-20250613","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/QAD.0b013e32835cee6e","article-title":"Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two phase III randomized trials.","volume":"27","author":"Cohen","year":"2013","journal-title":"AIDS"},{"key":"R16-20250613","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/QAD.0b013e32835e1554","article-title":"Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies\/ml or less: week 48 phase III analysis.","volume":"27","author":"Molina","year":"2013","journal-title":"AIDS"},{"key":"R17-20250613","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/INF.0000000000001275","article-title":"Rilpivirine as a treatment for HIV-infected antiretroviral-naive adolescents: week 48 safety, efficacy, virology and pharmacokinetics.","volume":"35","author":"Lombaard","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R18-20250613","doi-asserted-by":"crossref","first-page":"e0091621","DOI":"10.1128\/aac.00916-21","article-title":"Phase 2 open-label study of long-term safety, tolerability, and antiviral activity of rilpivirine in antiretroviral-naive adolescents living with HIV-1.","volume":"66","author":"Lombaard","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"R19-20250613","article-title":"Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse event. Version 2.1.","year":"2017"},{"key":"R20-20250613","article-title":"Guidance for Industry. Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment.","year":"2015"},{"key":"R21-20250613","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/135965350901400114","article-title":"Compilation and prevalence of mutations associated with resistance to non- nucleoside reverse transcriptase inhibitors.","volume":"14","author":"Tambuyzer","year":"2009","journal-title":"Antivir Ther"},{"key":"R22-20250613","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3851\/IMP3198","article-title":"Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents.","volume":"23","author":"Jantarabenjakul","year":"2018","journal-title":"Antivir Ther"},{"key":"R23-20250613","doi-asserted-by":"crossref","first-page":"2342857","DOI":"10.1155\/2019\/2342857","article-title":"Adrenal insufficiency: a forgotten diagnosis in HIV\/AIDS patients in developing countries.","volume":"2019","author":"Nassoro","year":"2019","journal-title":"Int J Endocrinol"},{"key":"R24-20250613","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa2108793","article-title":"Dolutegravir as first- or second-line treatment for HIV-1 infection in children.","volume":"385","author":"Turkova","year":"2021","journal-title":"N Engl J Med"},{"key":"R25-20250613","article-title":"The 2021 optimal formulary and limited-use list for antiretroviral drugs for children: policy brief.","year":"2021"},{"key":"R26-20250613","first-page":"783","article-title":"Antiretroviral therapy in children and adolescents: a look into modern single tablet regimens.","volume":"26","author":"Lee","year":"2021","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R27-20250613","article-title":"Guidelines for the use of antiretroviral agents in pediatric HIV infection.","year":"2024"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T22:03:45Z","timestamp":1749852225000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004828","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]}}}